Table 4.
Absolute and relative effects on renal outcomes in patients treated with SGLT2i versus placebo in CREDENCE and DAPA-CKD
| Outcomes | CREDENCE | DAPA-CKD | ||||
|---|---|---|---|---|---|---|
| Participants with an event per 1000 patient-years | CREDENCE, HR (95%CI) | Participants with an event per 1000 patient-years | DAPA-CKD, HR (95%CI) | |||
| Canagliflozin | Placebo | Dapagliflozin | Placebo | |||
| Renal composite outcomes | 27.0 | 40.4 | 0.66 (0.53–0.81) | 33 | 58 | 0.56 (0.45–0.68) |
| Decrease in eGFR ≥50% | NA | NA | NA | 26 | 48 | 0.53 (0.42–0.67) |
| Doubling of creatinine | 20.7 | 33.8 | 0.60 (0.48–0.76) | NA | NA | NA |
| RRT | 20.4 | 29.4 | 0.68 (0.54–0.86) | 25 | 38 | 0.64 (0.50–0.82) |
| eGFR <15 mL/min/1.73 m2 | 13.6 | 22.2 | 0.60 (0.45–0.80) | 19 | 28 | 0.67 (0.51–0.88) |
| Need for dialysis | 13.3 | 17.7 | 0.74 (0.55–1.00) | 15 | 22 | 0.66 (0.48–0.90) |
In DAPA-CKD, the number of events was expressed per 100 patient-years (here multiplied by 10 to present the results as in CREDENCE, i.e. per 1000 patient/years). eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; NA, not available.